Results, announced Wednesday and presented at the 48th San Antonio Breast Cancer Symposium (SABCS), showed the Tukysa-based combo cut the risk of ...
News
- Pfizer Builds Case for Tukysa as 'New Standard Regimen' in First-Line Metastatic Breast Cancer
- Intensity Therapeutics, Inc. to Present Two Posters at the 2025 - GuruFocus
... Biotechnology NAS:INTS. Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium. Author's Avatar.
- ADC Post-Endocrine Therapy Misses Mark in Advanced Breast Cancer Trial
SAN ANTONIO -- The antibody-drug conjugate (ADC) sacituzumab govitecan ... Biotechnology. Lathrop had no relevant financial disclosures ...
- Roche's Oral SERD Cuts Death Risk by 30% in Early-Stage Breast Cancer - BioSpace
Roche presented these findings at the 2025 San Antonio Breast Cancer Symposium (SABCS). ... biotech and science. He can be reached at tristan ...
- Celcuity Presents Updated Results from the PIK3CA Wild-Type Cohort of the Phase ... - StreetInsider
The additional study results were presented in an oral presentation session at the 2025 San Antonio Breast Cancer Symposium (“SABCS”) today, Thursday, ...